Publications, Posters and Presentations

<em>In vitro</em> Evaluation of Combination of Ibrexafungerp and Azoles against <em>Aspergillus</em> spp. Isolated from Lung Transplant Recipients

In vitro Evaluation of Combination of Ibrexafungerp and Azoles against Aspergillus spp. Isolated from Lung Transplant Recipients

Vidya Jagadeesan, Eileen Driscoll, Binghua Hao, Stephen Barat, Katyna Borroto-Esoda, Tom Chen, David Angulo, Cornelius J Clancy, M. Hong Nguyen
AAAM 2020
February 2020

Successful Treatment of a Patient with Retroperitoneal Abscess caused by <em>Candida krusei</em> with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study

Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study

George R. Thompson III, David Angulo
TIMM 2019
October 2019

<em>Candida auris</em> is Highly <em>In Vitro</em> Susceptible to Ibrexafungerp (formerly SCY-078) in EUCAST Antifungal Susceptibility Testing

Candida auris is Highly In Vitro Susceptible to Ibrexafungerp (formerly SCY-078) in EUCAST Antifungal Susceptibility Testing

Karin Meinike Jørgensen, Rasmus Krøger Hare, Anuradha Chowdhary and Maiken Cavling Arendrup
TIMM 2019
October 2019

Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against <em>Candida auris: In Vitro, In Vivo</em> and Clinical Case Studies of Candidemia

Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia

S. Barat, D. Angulo
TIMM 2019
October 2019

Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI study

GR Thompson, David Angulo
TIMM 2019
October 2019

Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of <em>Candida auris</em> Cutaneous Infection in a Guinea Pig Model

Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of Candida auris Cutaneous Infection in a Guinea Pig Model

M. Ghannoum, L. Long, C. Hager, K. Borroto-Esoda, S. Barat, and D. Angulo
ASM Microbe 2019
June 2019

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Padmaja Paderua, Stephen A. Barat, David Angulo, David S. Perlin, Yanan Zhao
ASM Microbe 2019
June 2019

$Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases<br><sup>Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)</sup>$

Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
^{Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)}

Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
April 2019

Successful Treatment of Two Patients with <em>Candida auris</em> Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

D Juneja, O Singh, B Tarai, DA Angulo
ECCMID 2019
April 2019

Favourable Clinical Outcome of Two Patients with <em>Candida</em> spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Philipp Koehler, Oliver A. Cornerly, David Angulo
ECCMID 2019
April 2019